You are here

Immune Checkpoint Blockade: Blocking Antibodies

Blockade of immune checkpoint molecules, such as CTLA-4 and PD-1/PD-L1, is a promising therapeutic approach for cancer treatment. Unfortunately, blocking CTLA-4 or PD-1/PD-L1 is not universally successful across different cancer types and patients. It is thought that co-targeting multiple checkpoint molecules simultaneously could improve the effectiveness of this strategy. Take advantage of the best blocking antibodies on the market to identify the next key immune checkpoint target.

R&D Systems® Blocking Antibodies

The selection and quality of our blocking antibodies is unparalleled. All of our blocking antibodies are tested in relevant bioassays and manufactured to ensure low endotoxin levels so you can always be confident in their performance. Learn more about what makes our blocking antibodies the best. Click the boxes below to view our selection of blocking antibodies for each molecule listed.

Explore More Products for T Cell Co-Signaling Molecules

Download the brochure below and explore our interactive pathway for an informative graphical outline of T cell co-stimulatory and co-inhibitory molecules and to learn about our extensive offering of antibodies, proteins, and ELISAs for this area of research.